Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies999
Asceneuron
Asceneuron is a biotech company that develops effective therapeutics for orphan tauopathies and Alzheimer's disease.
Sector
Subsector
Location
total rounds
total raised
Tranquis Therapeutics
Tranquis Therapeutics develops medicines to treat neurodegenerative and aging-related diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Caraway Therapeutics
Rheostat Therapeutics is a bio therapeutics company that develops novel drugs to treat neurodegenerative diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
AcureX Therapeutics
AcureX Therapeutics is a biotech company focused on halting neurodegenerative diseases, starting with Parkinson's Disease.
Sector
Subsector
Keywords
Location
total rounds
M&A Details1
Financials
Funding Rounds2
Investments4
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a global company focused on discovering and developing treatments for neurodegenerative diseases.
Sector
Subsector
Location
total rounds
total raised
Artax Biopharma
Artax Biopharma develops new therapies for autoimmune and inflammatory diseases.
Sector
Subsector
Location
total rounds
total raised
Aura Biosciences
Aura Biosciences is a biotechnology company that develops targeted therapies to destroy cancer cells while sparing healthy tissue.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors8
Number of lead investors
Number of investors
Partners Innovation Fund
The Innovation Fund accelerates healthcare technology development and attracts external capital.
Sector
Subsector
Location
count Of Investments
count Of Exists
Orion Healthcare Equity Partners
Orion Healthcare Equity Partners is a venture capital firm focused on health.
Sector
Subsector
Location
count Of Investments
count Of Exists
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Bruce Booth
Bruce is a Co-Founder and the Chairman of the Board at Kymera Therapeutics. He's also a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been instrumental in forming unique, innovative, and capital-efficient structures for drug discovery and development. He is a co-founder/founding investor and currently chair of the board of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. Along with Peter Barrett, Bruce seeded, incubated, and serves on the board of Zafgen (NASDAQ: ZFGN), and Bruce is a board member of Lysosomal Therapeutics Inc. (LTI) and Unum Therapeutics. Previously, he served on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. Previously, Bruce was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s private equity activities, ranging from early-stage venture capital through late-stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Bruce currently serves as a trustee of the New York Academy of Medicine and is a term member of the council on foreign relations. He received a DPhil from Oxford University as a Marshall Scholar and a BS from the Pennsylvania State University.
current job
People
Founders6
Kees Been
Kees Been is the Chief Executive Officer at BIAL Biotech Investments, Inc. Kees Been attended INSEAD.
current job
Kees Been
Dimitri Krainc
Dimitri is Aaron Montgomery Ward Professor of Neurology, Chairman of the Ruth and Ken Davee Department of Neurology at the Feinberg School of Medicine and Northwestern Memorial Hospital and Director of Center for Rare Neurological Diseases at Feinberg. Previously, he spent 20 years at Harvard Medical School completing his research training followed by a neurology residency and fellowship in movement disorders at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital. He then served on the clinical and research faculty in the Department of Neurology at MGH and Harvard Medical School.
current job
organization founded
Dimitri Krainc
Joseph Mazzulli
Joseph is assistant professor of neurology at the Northwestern University Feinberg School of Medicine. The major focus of his laboratory is to define mechanistic similarities between rare genetic lysosomal diseases and more common neurodegenerative disorders that are characterized by the accumulation of amyloid proteins, such as Parkinson's and Alzheimer's diseases.
current job
organization founded
Joseph Mazzulli
Edmund Sybertz
Ted Sybertz, Ph.D., held various research leadership positions at Schering Plough, Geltex and Genzyme, focusing on cardiovascular and CNS diseases. At Genzyme, he played a leadership role in discovery and preclinical development of the glucosyl ceramide synthesis inhibitor, eliglustat. He has been associated with the discovery and introduction of over 20 molecules into clinical development, six of which were ultimately approved.
current job
organization founded
Edmund Sybertz
Employee Profiles14
Dimitri Krainc
Scientific Founder, Chairman of the Scientific Advisory Board